KYMERA THERAPEUTICS INC. - COMMON STOCK

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

09 May 2025 06:01:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

09 May 2025 06:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference

07 May 2025 06:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025

24 Apr 2025 06:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

22 Apr 2025 05:59:59 By Nasdaq GlobeNewswire

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

09 Apr 2025 06:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

27 Feb 2025 06:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

26 Feb 2025 06:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

20 Feb 2025 06:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming February Investor Conferences

30 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

14 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

07 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

26 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

05 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

31 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

24 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

23 Oct 2024 06:15:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium

23 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader

09 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress

25 Sep 2024 06:00:00 By Nasdaq GlobeNewswire